

Evaluation of polygenic scoring methods in five biobanks reveals greater variability between biobanks than between methods and highlights benefits of ensemble learning

5 Remo Monti^{1,2}, Lisa Eick^{3*}, Georgi Hudjashov^{4*}, Kristi Läll^{4*}, Stavroula Kanoni^{5*}, Brooke N. Wolford^{6*}, Benjamin Wingfield^{7*}, Oliver Pain⁸, Sophie Wharrie⁹, Bradley Jermy³, Aoife McMahon⁷, Tuomo Hartonen³, Henrike Heyne¹, Nina Mars^{3, 10,11}, Genes & Health Research Team, Kristian Hveem⁶, Michael Inouye^{12,13,14,15,16,17}, David A. van Heel¹⁸, Reedik Mägi⁴, Pekka Marttinen⁹, Samuli Ripatti^{3,19,20}, Andrea Ganna^{3,20}, Christoph Lippert^{1,21,22,23}
*Equal contribution

Abstract

10 Methods to estimate polygenic scores (PGS) from genome-wide association studies are increasingly utilized. However, independent method evaluation is lacking, and method comparisons are often limited. Here, we evaluate polygenic scores derived using seven methods in five biobank studies (totaling about 1.2 million participants) across 16 diseases and quantitative traits, building on a reference-standardized framework. We conducted meta-analyses to quantify the effects of method
15 choice, hyperparameter tuning, method ensembling and target biobank on PGS performance. We found that no single method consistently outperformed all others. PGS effect sizes were more variable between biobanks than between methods within biobanks when methods were well-tuned. Differences between methods were largest for the two investigated autoimmune diseases, seropositive rheumatoid arthritis and type 1 diabetes. For most methods, cross-validation was more reliable for tuning
20 hyperparameters than automatic tuning (without the use of target data). For a given target phenotype, elastic net models combining PGS across methods (ensemble PGS) tuned in the UK Biobank provided consistent, high, and cross-biobank transferable performance, increasing PGS effect sizes (β -coefficients) by a median of 5.0% relative to LDpred2 and MegaPRS (the two best performing single methods when tuned with cross-validation). Our interactively browsable online-results
25 (<https://methodscomparison.intervenegeneticscores.org/>) and open-source workflow prspipe (<https://github.com/intervene-EU-H2020/prspipe>) provide a rich resource and reference for the analysis of polygenic scoring methods across biobanks.

¹ Hasso Plattner Institute, University of Potsdam, Digital Engineering Faculty, Potsdam, Germany

² Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin Institute for Medical Systems Biology, Berlin, Germany

³ Institute for Molecular Medicine Finland, FIMM, HiLIFE, University of Helsinki, Helsinki, Finland

⁴ Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia

⁵ William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK

⁶ K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health, Norwegian University of Science and Technology, Trondheim, Norway

⁷ European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK

⁸ Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom

⁹ Aalto University, Department of Computer Science, Espoo, Finland

¹⁰ Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA

¹¹ Stanley Center for Psychiatric Research and Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA

¹² Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

¹³ Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia

¹⁴ British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

¹⁵ Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, UK

¹⁶ British Heart Foundation Cambridge Centre of Research Excellence, School of Clinical Medicine, University of Cambridge, Cambridge, UK

¹⁷ Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, UK

¹⁸ Blizard Institute, Queen Mary University of London, UK

¹⁹ Department of Public Health, University of Helsinki, Helsinki, Finland

²⁰ Massachusetts General Hospital and Broad Institute of MIT and Harvard, Cambridge, MA, USA

²¹ Windreich Dept. of Artificial Intelligence & Human Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA

²² Hasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, USA

²³ Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

30 Introduction

Polygenic scores (PGS), also referred to as polygenic risk scores (PRS), have become a major application of genome-wide association studies (GWAS). PGS are constructed by scoring individuals based on their genotype, adding up effects of many genetic variants genome-wide. They can improve existing disease risk models that rely on family history and established biomarkers¹⁻⁴, and individuals in the upper tail of the PGS distribution have an elevated disease risk similar to that caused by rare damaging monogenic mutations for some diseases⁵. PGS have received attention in areas ranging from disease prevention to clinical trials, owing to their wide applicability to personalized medicine⁶⁻⁹.

Various methods to derive PGS weights from GWAS summary statistics (effect sizes and their correlation structure) have been developed. These methods are of particular interest as they do not rely on access to individual-level data, which is typically restricted. Furthermore, the largest GWAS are meta-analyses, for which direct access to all individual-level source data is not feasible.

The construction of a PGS from summary statistics can be divided into two main stages: A public stage, that relies only on publicly available data and tools, and a private stage that requires access to individual-level target data, i.e., genotypes and phenotypes. The public stage uses variant correlation (linkage disequilibrium; LD) from reference panels that are matched in ancestry to the GWAS sample to adjust the marginal effect size estimates of genetic variants and derive the per-variant PGS weights. These adjustments include frequentist shrinkage¹⁰, Bayesian approaches¹¹⁻¹⁵, or other strategies like thresholding, which depend on one or more hyperparameters (e.g., p-value thresholds, heritability estimates, or shrinkage parameters).

Many methods allow automatically setting suitable parameters without the use of phenotype data (we refer to this generally as automatic tuning). Alternatively, target data can be used to empirically determine hyperparameters based on, for example, cross-validation (CV). The adjusted variant effect sizes (PGS weights) are used in the private stage to score individuals based on their genotypes using a linear additive model, i.e., to calculate their PGS.

PGS method authors usually claim superior performance to other methods. However, comparisons are often limited to a small number of methods, traits, or target datasets.

Furthermore, the input summary statistics used in those comparisons may not reflect the

properties of (messy) real-world data, especially those from meta-analyses. In practice, other factors also affect performance, e.g., ease of use and documentation.

The INTERVENE consortium¹⁶ seeks to develop risk scoring methods that integrate PGS with other health-related information. For this reason, we compared summary-statistics-based
65 PGS methods. Building on the GenoPred suite introduced by Pain et al. that implements different PGS methods in a reference standardized framework¹⁷, we developed prspipe, a snakemake¹⁸ workflow that runs seven polygenic scoring methods. A full evaluation including hyperparameter tuning with cross-validation was performed in the UK Biobank¹⁹ (UKBB) and replicated in FinnGen²⁰, Estonian Biobank²¹ (EBB), the Trøndelag Health
70 Study²² (HUNT) and Genes & Health²³ (GNH). In total, we meta-analyzed performances for ten binary disease traits and six quantitative traits in two replicated ancestry groups European (EUR) and South Asian (SAS). Replication in multiple biobanks allowed us to estimate how much PGS effect sizes vary within biobanks (between methods) and how this compares to the variation between biobanks.

75 We publish our workflow, summary data, and PGS weights, allowing others to replicate analyses e.g., for methods comparisons or developing new polygenic scores from summary statistics. The results of this analysis are made available in a browsable online resource at <https://methodscomparison.intervenegeneticscores.org/>.

Results

80 Prspipe workflow and experimental setup

We created a snakemake workflow prspipe to run different polygenic risk scoring methods based on GWAS summary statistics. Prspipe makes it possible to automate the within-biobank analyses from Pain et. al.¹⁷ based on the GenoPred suite of scripts (<https://github.com/intervene-EU-H2020/GenoPred>). Notable differences include an updated
85 set of methods (p-value thresholding and clumping (pT+clump), lassosum¹⁰, PRScs¹¹, LDpred2¹³, DBSLMM¹⁴, SBayesR¹² (robust parameterization) and MegaPRS¹⁵), the use of LD reference panels provided by the methods' authors, and software managed partially with containers. We used prspipe to derive PGS weights using both methods' automatic settings (auto), and grids of hyperparameters (MegaPRS, LDpred2, PRScs, lassosum, and
90 pT+clump)¹⁷. For the baseline method pT+clump, we considered the score with the most stringent p-value threshold ($p < 1e-8$, i.e., keeping only highly significant variants) as the automatically tuned score.

The workflow defines steps to set up PGS methods, download and process summary statistics from the NHGRI-EBI GWAS Catalog²⁴, run PGS methods (i.e., the derivation of PGS weights), target genotype harmonization, ancestry matching based on the 1000 Genomes superpopulations²⁵, and target polygenic scoring with plink2²⁶. As PGS performance depends on the genetic similarity of the target and GWAS samples²⁷, performance evaluation is stratified according to the matched superpopulation. Using CV, elastic net models combining scores from different methods are fit (ensemble PGS), and the best single PGS weights are selected for each method (hyperparameter tuning)¹⁷.

We applied this workflow to 14 sets of summary statistics from the GWAS Catalog to derive PGS and predict six continuous traits and 10 binary disease traits derived from harmonized ICD-code-based definitions²⁰ (Methods, Table 1). Our main analyses focus on the two replicated ancestry-reference-matched superpopulations: EUR and SAS. The number of cases used for performance evaluation across biobanks ranged from 5,384 (T1D) to 81,487 (type 2 diabetes; T2D) for EUR, and 60 (RA, available in GNH only) to 8,696 (T2D) for SAS ancestry matched target data. The total sample size for performance evaluation for continuous traits ranged from 85,973 (urate, available in UKBB only) to 524,056 (height) for EUR target data, and 13,572 (urate) to 43,197 (height) for SAS target data (Table 2).

Using 80% of the UKBB EUR target data (training set), we selected the best performing weights for each method and fit ensemble PGS (full workflow). PGS weights were shared with other biobanks, in which we still performed target data harmonization, ancestry matching, and polygenic scoring steps needed for performance evaluation (Figure 1).

Browsable results, meta-analysis and ranking

As outlined in Figure 2 for T2D, we calculated PGS effect sizes for continuous and binary traits across all target biobanks and ancestries (Supplementary Tables 1-3, Supplementary Figures 1-5) and performed mixed model meta-analyses within ancestry groups to determine the best performing PGS (the one with the largest effect size) for each trait across biobanks (Supplementary Table 4-6). Additionally to scores produced by single methods, we evaluated the UKBB-tuned ensemble PGS in other biobanks after projecting them back to the variant-level (Methods). For each trait, we meta-analyzed β -coefficients (i.e., the change in the trait per PGS standard deviation, on the log-odds scale for binary traits, in standard deviations for continuous traits) of up to 13 PGS corresponding to different tuning types (auto or CV) for seven methods and the UKBB-EUR-tuned ensemble PGS (Supplementary Figure 6).

125 Other than the ensemble PGS, we found that CV-tuned PGS from LDpred2 and MegaPRS
ranked highly across traits (Figure 3). The median relative increase in PGS effect size over
CV-tuned pT+clump was 29.2% for CV-tuned LDpred2 (mean 30.9%±10.3sd, N=12, EUR)
and 29.9% for CV-tuned MegaPRS (mean 31.2%±12.6 sd, N=12, EUR), showing overall
comparable performance (the median relative difference between the two was 0.1% in favor
130 of MegaPRS).

Scores produced by automatic tuning appeared overall less reliable, especially for LDpred2
(see Discussion) and SBayesR (as previously described¹⁷). Although automatic tuning
typically outperformed the baseline method pT+clump, we observed seemingly non-
systematic cases of reduced relative performance (e.g., SBayesR for urate/gout, DBSLMM
135 for Alzheimer's disease, or LDpred2 for HbA1c or RA) (Supplementary Figure 11).
MegaPRS was the best automatically tuned method (median 23.3% relative increase over
CV-tuned pT+clump, mean 27.4%±15.9 sd, EUR), yet PGS effect sizes were comparatively
low for some continuous traits (e.g., BMI, HDL, or height, Supplementary Figure 11).
Effect size differences between the top PGS by single methods were mostly not significant
140 (Supplementary Figure 7, FWER ≤ 0.05, two-sided z-test). We also provide these data on
the level of individual biobanks (Supplementary Figure 9-10), revealing that the best single
method was not necessarily consistent between biobanks.

UKBB-tuned ensemble PGS outperforms other methods

The ensemble PGS ranked favorably for all traits in EUR- and SAS-matched target data
145 (Figure 3) except for T1D in EUR (driven by lower performance in FinnGen) and stroke in
SAS (the trait with the overall lowest performance). For EUR target data, effect sizes were
significantly greater than those of all other PGS for 6/9 binary and 5/5 continuous traits
(FWER ≤ 0.05, two-sided z-test) and the largest overall in 13/14 traits for which we fit
ensemble PGS. These results stood out compared to those for single methods, which did not
150 produce a consistent best method and for which differences were mostly not significant.
Compared to the best single methods, the median relative increase in effect size was 3.7%
over CV-tuned LDpred2 and 4.5% over CV-tuned MegaPRS for binary disease traits (N=9).
Median relative increases for continuous traits were larger (5.2% and 7.9%, respectively,
N=5). When measured in terms of variance explained, relative differences were larger. We
155 observed median relative increases of 7.4% and 9% for binary traits (liability scale) and
10.7% and 16.1% for continuous traits, respectively (Supplementary Figure 8, Supplementary
Table 7). Similar trends were observed for SAS target data, with the ensemble PGS having

the largest effect size in 12/13 traits, albeit its effect size was only significantly larger than all others for continuous traits urate, eGFR and HDL (FWER \leq 0.05, two-sided z-test). We
160 report relative effect sizes of all methods relative to the ensemble PGS in Table 3.

CV-tuning increases PGS robustness

Hyperparameter tuning with cross-validation using the UKBB EUR data was often beneficial and rarely harmful when evaluated on EUR target data (Figure 3). CV-hyperparameter tuning strongly increased effect sizes in a subset of traits for specific methods, rather than providing
165 large benefits across traits (Supplementary Figure 12-13). pT+clump benefited most from CV-tuning when evaluated on EUR target data, i.e., selecting p-value thresholds larger than the baseline 1e-8 was always beneficial (median 12.8% increase in effect size), followed by lassosum (median 6.2% increase) and LDpred2 (median 4.1% increase). MegaPRS and PRScs benefited the least (median 1.2% and 0.2% increase, respectively). For SAS target
170 data, the median benefits were smaller, except for PRScs (Supplementary Table 8) and overall less consistent (Figure 3). Mean increases were larger for all methods except for PRScs in EUR target data, often dominated by few instances in which automatic tuning had comparatively low performance.

The performance increases seen by CV-tuning were by and large significant when evaluated
175 in EUR target data (Figure 3, FWER \leq 0.05, two-sided z-test), except for PRScs which only saw an improvement for two phenotypes. Significant negative effects of CV-tuning for EUR data were only observed for RA (PRScs and MegaPRS, driven by FinnGen) and CKD (PRScs, Supplementary Figure 12). For SAS target data, we observed fewer significant differences, and PRScs was the only method for which we observed a significant reduction in
180 effect size (BMI, Supplementary Figure 13). A more detailed description of these comparisons is provided in the Supplementary Results.

Tuned PGS performance varies more between biobanks than between methods within biobanks

We estimated PGS effect size heterogeneity between biobanks and how it compares to the
185 heterogeneity between methods within biobanks using 3-level meta-analytic random effects models in EUR target data (Methods). These nested models have two random effect parameters: τ^2_{biobank} and τ^2_{method} . τ^2_{biobank} captures effect-size heterogeneity due to differences between biobanks, and τ^2_{method} captures heterogeneity due to differences between methods within biobanks (we report their square roots τ_{biobank} and τ_{method} , as they are on the same scale
190 as the PGS effect sizes). Additionally, we estimated I^2_{biobank} and I^2_{method} , which quantify the

overall fraction of variance (between 0 and 1) in effect sizes attributable to biobank or choice of method within biobank, respectively.

We focused on scores selected via cross-validation in the UKBB-EUR sample (if available) and excluded scores from SBayesR that performed poorly in the UKBB-EUR 80% training data (RA, T1D, BMI, urate/gout). We did not consider the ensemble PGS or baseline method pT+clump, meaning that up to 6 scores were considered per trait. This setting was chosen to mimic the case in which multiple validated PGS from standard methods are available.

We found significant heterogeneity of PGS effect sizes in all 13 traits replicated in at least two biobanks ($\text{FWER} \leq 0.05$, Cochran's Q -test, accounting for 13 tests). The target biobank had a larger influence on the PGS effect size than the choice of method within biobank across all traits (i.e., $\tau_{\text{method}} < \tau_{\text{biobank}}$, Figure 4, Table 4). However, likelihood-based 95% confidence intervals for τ_{biobank} were large and sometimes included the estimate for τ_{method} (RA, stroke, T2D) and 0 (T1D, breast cancer). The variation in PGS effect sizes could to a large degree be explained by heterogeneity between biobanks (average $I^2_{\text{biobank}} = 82.9\% \pm 14.3$ sd, $N = 13$) and, to a lesser degree by heterogeneity between methods (average $I^2_{\text{method}} = 11.97\% \pm 12.4$ sd, $N=13$).

Effect sizes for inflammatory bowel disease and RA varied most between biobanks (τ_{biobank}), also when adjusting for the average effect size ($\tau_{\text{biobank}}/\mu_{\beta}$). Effect sizes for BMI varied the least between biobanks, both absolutely (τ_{biobank}) and relative to the average effect size ($\tau_{\text{biobank}}/\mu_{\beta}$). For binary traits, effect sizes for breast cancer varied the least across biobanks, both absolutely and relative to the average effect size.

Across traits, τ_{method} was correlated with the average effect size (Pearson correlation 0.54, $p = 0.0558$, t -statistic = 2.1377, 11 degrees of freedom), especially when removing T1D and RA (Pearson correlation 0.85, $p = 0.00094$, t -statistic = 4.83, 9 degrees of freedom), i.e., we found a linear relationship between the differences between methods and overall effect size, especially in the set of non-autoimmune traits.

τ_{biobank} was less correlated with the meta-analyzed average effect size (Pearson correlation 0.367, $p = 0.219$, t -statistic = 1.30, 11 degrees of freedom), i.e., large PGS effect sizes weren't necessarily associated with higher variability between biobanks.

For SAS ancestry target data, we did not find significant heterogeneity of PGS effect sizes in CKD, stroke, prostate cancer, or breast cancer ($\text{FWER} \leq 0.05$, Cochran's Q -test, accounting for 11 tests) and τ_{biobank} could never reliably be estimated (Supplementary Figure 14).

Likelihood-based 95% confidence intervals for τ_{biobank} included 0 for 9/11 replicated traits (all but T2D and eGFR).

225 High variability between PGS methods for autoimmune diseases

Effect sizes were most variable between methods for autoimmune diseases T1D and RA (τ_{method}) (Supplementary Figure 15), even when accounting for the average effect size in those traits ($\tau_{\text{method}}/\mu_{\beta}$), or relative to the total variation of effect sizes (I^2_{method}). The scores for T1D and RA also had the largest fraction of PGS variance originating in the HLA region (mean 230 0.7 ± 0.12 sd and 0.54 ± 0.21 sd, respectively) (Supplementary Figure 16). For T1D, the method with the largest effect size appeared to be biobank-specific, with FinnGen favoring PRSs, while the UKBB and EBB had significantly larger effect sizes for LDpred2 and MegaPRS (forest plots for all 3-level meta-analytic models are available in the Supplementary Data). In contrast, effect sizes for BMI and HDL varied the least between 235 methods.

Regarding SAS-matched target data, RA was only available in GNH with a limited number of cases (60) but displayed the highest heterogeneity of effect sizes due to method ($\tau_{\text{method}} = 0.137$, 95% CI: 0.046-0.379), consistent with the findings in EUR ancestry. T1D scores were not predictive in GNH (Supplementary Figure 1), and not evaluated in the UKBB due to 240 small sample size, therefore, we couldn't replicate the related findings from the EUR subset.

Discussion

With this study, we have provided to our knowledge the most comprehensive systematic PGS method comparison to date. By publishing our workflow, we aim to increase access to PGS methods and facilitate future research. We believe that PGS method software could be greatly 245 improved by support for standard formats (e.g., those maintained by the GWAS Catalog and PGS Catalogs²⁸) alongside software containerization (containers were supported in all the research environments that contributed to this study).

Our analysis was based on a previously published framework¹⁷ which we automated, and expanded application and evaluation to multiple biobanks. Methods explicitly tailored for 250 diverse target populations or source GWAS were missing in this framework, and diverse ancestries were not well represented in our target data, which provides a limitation of this study. PGS tuning was performed in one biobank (UKBB-EUR) relying largely on author-provided LD reference panels. This approach more closely resembles real-world PGS application and allowed us to harness the full sample sizes in other biobanks/ancestries to 255 maximize statistical power, and test transferability.

Importantly, we were unable to identify a single method that consistently outperformed all others (not counting the ensemble PGS), and the two highest performing methods (CV-tuned

MegaPRS and LDpred2) were virtually tied. The best automatically tuned method was MegaPRS, albeit like other automatic methods it suffered sporadic cases of comparatively lower performance. Which method performs best may vary based on the specifics of the GWAS summary statistics, trait, and target sample. Given that the best methods performed so similarly, other modelling choices not investigated here (such as the set of included variants and their availability in the target sample) may well tip the balance in favor of one or the other when starting from the same GWAS summary statistics. Based on our results, we recommend tuning with cross-validation (with sufficiently large ranges of hyperparameters) instead of using methods' automatic settings, primarily to prevent cases of comparatively lower performance, rather than providing large improvements across traits.

One reason for the lower performance of automatic tuning could be model misspecification, e.g., mismatched LD-references, or misreported fields in the input summary statistics. These inconsistencies may not be considered when tools are developed. The variable performance of LDpred2-auto stood out particularly against the high performance of CV-tuned PGS from same method. We note that LDpred2-auto has been updated at the time of writing including an optional new parameterization, which could affect its performance²⁹.

This highlights a challenge faced by any method comparison: The frequent emergence of new tools and methods means that comparisons risk becoming outdated shortly after execution. Method evaluation across multiple biobanks can hardly match the pace of new developments. We therefore caution against using the results of this study to make definitive claims about relative method performance of actively developed methods. A more sustainable approach to method comparisons would be decentralized, with researchers individually submitting performance estimates for published scores (starting from the same summary statistics and variants) to a central repository and receiving credit by having such submissions be referenceable.

Using meta-analytic mixed models, we found that the performances of well-tuned PGS varied more between biobanks than within biobanks. This likely reflects heterogeneity in phenotyping (e.g., disease diagnosis practices) rather than differences in population structure or genotyping. Effect sizes for BMI, which presumably is consistently measured, varied the least between biobanks, supporting this hypothesis. The variability between biobanks for some traits implies that scores need to be re-evaluated when switching between different target data even when comparing ancestry-matched populations.

We note that the parameters by which we quantified variability are sensitive to which biobanks and PGS are included. The setting we chose mimics the case in which multiple

UKBB-EUR-validated PGS are available. The variability between methods could increase if poorly performing (non-validated) scores are included in the analysis. On the other hand, the variability between biobanks could decrease if, e.g., phenotype definitions were further
295 refined.

We found particularly large differences between methods for autoimmune diseases T1D and RA. This could be driven by the way methods handle the HLA-region, as well as genotyping differences in the target biobanks. Our analyses highlight modelling of the HLA-region as an area in which methods could potentially be improved.

300 One of the most useful insights from this study is that ensemble PGS tuned in the UKBB-EUR sample provided consistently strong performance, albeit at the cost of higher computational demand during training. We see this method as complimentary to cross-trait prediction strategies (MultiPGS)³⁰⁻³² that use PGS constructed from multiple sets of GWAS summary statistics (from different traits). Considering the small differences in performance
305 we observe for well-tuned scores from single methods, we see ensemble PGS and MultiPGS as promising avenues to further improve PGS performances beyond what is currently possible with single methods. Future research needs to assess how well EUR-trained ensemble PGS transfer to other genetic ancestries. It is possible that training needs to be performed in a population similar to the target population to ensure optimal performance and
310 avoid exacerbating already existing issues with current PGS⁷.

In Summary, while no single method outperformed all others, method ensembles provided consistently strong performance (with few exceptions). PGS effect size heterogeneity between biobanks was larger than between methods within biobanks, likely pointing to challenges with phenotyping. Large heterogeneity between methods was observed for
315 autoimmune diseases, indicating that special care should be taken for PGS which rely heavily on the HLA region. Our open-source workflow, analyses framework and online results provide a rich ground for future method benchmarking and development.

Methods

Participating Studies

320 Data from five biobanks were considered: The UK Biobank, FinnGen, Estonian Biobank, Trøndelag Health Study (HUNT) and Genes & Health. All biobanks independently performed genotyping, imputation, and variant quality control.

GWAS summary statistics selection and processing

We selected summary statistics from the GWAS catalog for eight binary traits and for five
325 continuous traits. Table 1 shows GWAS catalog study identifiers and traits. Where available,
we directly used the pre-harmonized summary statistics provided by the GWAS catalog. For
GWAS catalog studies GCST90013445³³ (T1D), GCST008972³⁴ (urate), GCST007954³⁵
(HbA1c) and GCST004773³⁶ (T2D) we used the MungeSumstats R package³⁷ (version 1.0.1)
to retrieve missing fields (e.g., variant positions). GWAS variants were matched to the
330 HapMap3-1KG variants based on positions and allele codes and renamed accordingly. Other
quality control steps are flipping of variants to match the HapMap3-1KG reference, variant
frequency filtering (>1%), removal of variants with invalid p-values (>1 or <0), ambiguous
variants, variants with missing data, duplicate variants, or variants with sample size more
than three standard deviations away from the median per-variant sample size (if available), as
335 previously described¹⁷.

We selected GWAS studies with predominantly European ancestry discovery samples,
because the evaluated biobanks primarily contain individuals of European ancestry. Because
we use the UKBB for evaluation and score selection, we selected for studies with large
sample sizes that preferably did not include the UKBB in the discovery sample. Yet, the
340 selected summary statistics for AD and height included the UKBB-EUR data, which was then
excluded from performance estimation for those phenotypes, from hyperparameter tuning
with cross validation, and ensemble PGS.

Reference genotype harmonization

We constructed our own definition of the HapMap3-variants³⁸ to avoid favoring one of the
345 definitions used by the PGS methods. We retrieved HapMap3 variant rsids, and downloaded
genotypes for the 1000 Genomes reference from
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/working/20140708_previous_phase3/v5_vcf/
(v5). We retrieved updated rsids for all 1000 Genomes variants using the Bioconductor
SNPlocs.Hsapiens.dbSNP144.GRCh37 R-package³⁹ (the latest version for the GRCh37
350 genome-build at the time) based on GRCh37 variant positions and allele codes, and
intersected them with the HapMap3 variants based on rsids. We then mapped these variants
from GRCh37 to GRCh38 using liftOver⁴⁰ and retrieved rsids in that genome build too, based
on location and allele codes, using the SNPlocs.Hsapiens.dbSNP151.GRCh38 R-package³⁹
(the latest version for the GRCh38 genome-build at the time). We retained variants with an

355 allele frequency of at least 1% in any of the 1000 Genomes superpopulations. These variants (HapMap3-1KG, N = 1,330,821) form the basis for subsequent analyses.

The list of variants including GRCh37 (hg19) and GRCh38 (hg38) coordinates, rsids, and allele frequencies in the 1000 Genomes superpopulations is available on [https://github.com/intervene-EU-](https://github.com/intervene-EU-H2020/prspipe/blob/main/resources/1kg/1KGPhase3_hm3_hg19_hg38_mapping_cached.tsv.gz)

360 H2020/prspipe/blob/main/resources/1kg/1KGPhase3_hm3_hg19_hg38_mapping_cached.tsv.gz. Scripts to reproduce these steps are available as part of the prspipe workflow

([https://github.com/intervene-EU-](https://github.com/intervene-EU-H2020/prspipe/blob/main/workflow/rules/1kg_hm3_processing.smk)

[H2020/prspipe/blob/main/workflow/rules/1kg_hm3_processing.smk](https://github.com/intervene-EU-H2020/prspipe/blob/main/workflow/rules/1kg_hm3_processing.smk)). The filtered and intersected 1000 Genomes genotypes are provided as a separate resource. Variants are further

365 filtered when constructing polygenic scores, as described below.

Target genotype harmonization

Target genotype data were intersected with the HapMap3-1KG variants based on positions and allele codes, renamed, and converted to plink1 format. The harmonized data served as input to all subsequent analyses involving target genetic data, i.e., ancestry reference

370 matching and polygenic scoring. Target harmonization is part of the prspipe workflow and corresponding steps are defined in [https://github.com/intervene-EU-](https://github.com/intervene-EU-H2020/prspipe/blob/main/workflow/rules/genotype_harmonization.smk)

[H2020/prspipe/blob/main/workflow/rules/genotype_harmonization.smk](https://github.com/intervene-EU-H2020/prspipe/blob/main/workflow/rules/genotype_harmonization.smk).

Binary disease phenotype harmonization

We used expert curated ICD-code based definitions^{20,41} developed at FinnGen to define

375 binary disease traits (referred to as endpoints). Individuals were counted as cases for a specific endpoint if they matched ICD-9- or ICD-10-code-based inclusion/exclusion criteria (Supplementary Table 13). The remaining (non-matching) individuals for that endpoint were counted as controls. All data used to define binary disease endpoints were registry based.

breast cancer was only evaluated when the reported sex was female, and prostate cancer only

380 when the reported sex was male.

For the UKBB, we considered both main (data-fields 41202 and 41203) and secondary (data-fields 41204 and 41205) ICD-9 and ICD-10 diagnosis codes derived from hospital inpatient admissions.

Continuous trait definitions

385 For the UKBB, we used the following data-fields to define continuous traits: 50 for height, 21001 for BMI, 30700 for creatinine, 30750 for HbA1c and 30880 for urate.

For GNH, we considered all instances where a continuous trait was measured per individual through their primary and secondary health records. We removed outliers based on a 6SD deviation per trait and calculated the mean value per trait per individual to use in the analysis.

390 For HUNT, the latest value was chosen when continuous traits were measured at more than one baseline enrollment or sub-study screening over three recruitment waves since 1984. Standard quality assessment measures were taken across variables and are described at the HUNT Databank (<https://hunt-db.medisin.ntnu.no/hunt-db/variablelist>). BMI was defined by height and weight measured at screening. HDL and creatinine were measured from serum in
395 non-fasting individuals. HbA1C was measured in mmol/mol according to the international federation of clinical chemistry (IFCC) standard.

For Estonian Biobank, the earliest value available were chosen for BMI and height, as some individuals are repeatedly measured. Height values larger than 260 or smaller than 100 were omitted. Similarly, BMI values less than 10 or larger than 200 were discarded. Metabolic
400 profiles for HDL and creatinine were obtained with NMR for a random subset of Estonian biobank (n=10681).

For each biobank in which creatinine measurements were available, we calculated the eGFR based according to the diet in renal disease study equation⁴², as follows:

$$eGFR = \alpha \times S_{cr}^{-1.154} \times age^{-0.203} \times \sigma$$

405 Where α is 30849 if creatinine was measured in $\mu\text{mol/l}$, or 175 if measured in mg/dl , S_{cr} is the serum creatinine measurement and σ is 0.742 if the reported sex is female, or 1 if sex is male. We did not include the multiplier for “ethnicity” as we only perform comparisons within ancestry-matched populations. During evaluation, all continuous traits are standardized to mean 0 and unit standard deviation.

410 Polygenic score weight derivation

We derived polygenic scoring weights with pT+clump, lassosum, PRSCs, SBayesR (robust parameterization), LDpred2 and DBSLMM using the settings described previously¹⁷. For MegaPRS, we used the author-recommended BLD-LDAK heritability model and specified “-
-model mega” to fit many different scores with different tools (lasso, bolt, ridge, bayesr) and
415 included the HLA region, as recommended. Software versions and sources for each tool are listed in Supplementary Table 14.

Besides letting methods determine suitable hyperparameters based on the summary statistics alone (automatic tuning), we generated scores over grids of hyperparameters for target-data-based tuning with 10-fold cross-validation (see below).

420 We used European ancestry LD reference panels for all analyses, as the selected GWAS were performed in majority European ancestry samples. In contrast to Pain et al., we use PGS method author-provided LD-references for DBSLMM, lassosum, LDpred2, SBayesR and PRSCs. DBSLMM and lassosum LD-references are based on the 1000 Genomes data. For LDpred2, SBayesR, and PRSCs they are based on UKBB data. We use the 1000 Genomes
425 EUR-subset to calculate LD when running pT+clump and MegaPRS. Scripts to download PGS method software and data are part of the prspipe workflow. The workflow uses GenoPred scripts to generate plink2-compatible scoring files.

Ancestry matching and genetic outlier removal

Rather than directly inferring genetic ancestry, we score individuals according to their
430 similarity with groups defined in the 1000 Genomes reference²⁵. We use GenoPred Ancestry_identifier.R to project target genetic data into the 1000 Genomes genetic principal component space, and match individuals to one of the five 1000 Genomes superpopulations (AFR, AMR, EAS, EUR, SAS). Both the target and 1000 Genomes genotype data are filtered to variants available in both samples (subset of HapMap3-1KG) with allele frequencies above
435 5%, missingness below 2%, and variants that do not violate Hardy Weinberg equilibrium ($p < 1e-6$). Regions of long LD are excluded⁴³ and variants are LD-pruned based on the 1000 Genomes reference (using plink "--indep-pairwise 1000 5 0.2"). Genetic PCs are derived in the 1000 Genomes based on the filtered variants, and an elastic net classifier is fit with 5-fold cross validation to place individuals into one of the five groups based on 100 PCs. Target
440 genotype data are projected into the same PC space using plink, and the classifier is used to predict the most matching superpopulation for all individuals.

Additionally, we used GenoPred Population_outlier.R to remove extreme outliers within the assigned ancestry-matched groups in the target data based on the first eight genetic principal components constructed within those groups. We used the same variant filters described
445 above (except that LD-pruning was now performed within the target data), calculate genetic PCs within the assigned groups, and define up to ten centroids in the PC space using R NbClust⁴⁴ (distance = 'euclidian', method = 'kmeans'). For each centroid, the Euclidian distance of individuals to the center is calculated and those with distances that are larger than the 75th percentile + 30 IQR are removed (i.e., extreme outliers). The UKBB was the only
450 biobank that had more than one ancestry group well-represented. Our analyses focus on the replicated groups EUR (UKBB, EBB, HUNT, FinnGen) and SAS (UKBB, GNH).

Polygenic scoring

We performed polygenic scoring for scores derived by single methods with plink2 using GenoPred Scaled_polygenic_scorer_plink2.R. Polygenic scoring is part of the prspipe
455 workflow. For the evaluation of the ensemble PGS, we performed scoring with plink2. In both cases, missing genotypes are imputed using the 1000 Genomes matched superpopulation allele frequencies as previously described¹⁷.

Hyperparameter tuning and ensemble PGS

For the methods that generate scores over a range of hyperparameters (pT+clump, lassosum,
460 PRSs, LDpred2) we used 10-fold cross validation to select the score with the largest correlation with the trait, as described previously¹⁷. Where available, we included scores produced by methods' automatic settings in the selection process. We perform cross-validation using 80% of the UKBB EUR data and retain 20% for evaluation (we used different subsamples for each trait in order to perform stratified sampling).

465 For pT+clump, we define the score given by the p-value threshold of 1e-8 as the automatically tuned score. SBayesR and DBSLMM only use automatic settings, i.e., they produce just a single set of weights and are not tuned with CV.

To fit the ensemble PGS, we include all scores from all methods across hyperparameters, and use 10-fold CV to determine suitable shrinkage parameters for an elastic net model
470 combining the different scores with the caret R-package⁴⁵ (which relies on glmnet⁴⁶). For tuning of the ensemble PGS, we used non-nested scores for pT+clump, i.e., scores with disjoint variant sets corresponding to 10 p-value bins. These steps were performed with GenoPred Model_builder_V2.R and are part of the prspipe workflow.

To score other biobanks with the UKBB ensemble PGS, we generated plink2-compatible
475 scoring files by multiplying the PGS weights of every variant with their corresponding weights in the ensemble PGS model and adding them (yielding a single weight for each variant).

Performance evaluation within biobanks

All PGS were standardized to mean zero and unit standard deviation within biobanks and
480 ancestries for performance evaluation. We calculated the following metrics for binary disease traits: β coefficients, i.e., the change in log-odds ratios per PGS standard deviation, the change in odds ratio per PGS standard deviation ($OR = \exp(\beta)$), fraction of variance explained on the observed scale (r^2_{obs}) and the area under the receiver operating characteristic curve (AUROC). The variance explained on the liability scale (r^2_{liab}) was calculated from

485 r_{obs}^2 ⁴⁷ using the median prevalence within ancestries as the population prevalence estimate
(Supplementary Table 1). We retrieved DeLong 95% confidence intervals⁴⁸ for the AUROC
using the `ci.auc`-function in the `pROC` R-package. Confidence intervals for r_{obs}^2 were derived
from 1000 bootstrap samples of r_{obs} (the Pearson correlation on the observed scale) for binary
traits.

490 For continuous traits, we calculated β coefficients, i.e., the change in standard deviations of
the trait per standard deviation of the PGS and the fraction of variance explained (r_{obs}^2).

When comparing two effect sizes of scores $\beta_{a,i}$ and $\beta_{b,i}$ within biobank “i”, we use the two-
sided z-test and adjust for the correlation between scores, with test statistic:

$$z = \frac{\beta_{a,i} - \beta_{b,i}}{\sigma}$$

495 ,where

$$\sigma = \sqrt{\sigma_{a,i}^2 + \sigma_{b,i}^2 - 2\rho_{(a,b),i}\sigma_{a,i}\sigma_{b,i}}$$

With $\sigma_{a,i}$ and $\sigma_{b,i}$ denoting the standard deviations of $\beta_{a,i}$ and $\beta_{b,i}$, respectively and $\rho_{(a,b),i}$
denoting the correlation between scores “a” and “b” measured in biobank “i”.

Data Exclusions before meta-analyses

500 None of the scores evaluated in GNH-SAS for T1D reached nominal significance ($p < 0.05$,
two-sided z-test) for association with the endpoint (Supplementary Table 1), and all effect
sizes were close to zero. We removed these data from further analysis. We found strongly
reduced effect sizes of scores for HbA1c in GNH-SAS compared to the UKBB-SAS
(Supplementary Table 2, Supplementary Figure 1) and decided not to include these data for
505 meta-analyses (it was unclear if reduced performance was due to a phenotyping issue). We
found low effect sizes compared to other biobanks for T1D in HUNT (Supplementary Figure
1), determined it was likely due to a phenotyping issue, and excluded those data from meta-
analyses.

Meta-analysis for methods comparisons

510 All Meta-analyses were performed in R (version 4.1.1) with the `metafor` package (`rma.mv`
function, version 3.8-1), using the `V`-argument to account for the dependence of effect-sizes
within biobanks (see below), and models were fit with REML.

We meta-analyzed the β coefficients of scores across biobanks within ancestries and traits
using meta-analytic mixed effects models. The observed β coefficients are modelled as

515 follows:

$$\beta_{s,b} = \alpha w_s + \zeta_b + \epsilon_{s,b}$$

Where $\beta_{s,b}$ is the observed coefficient for PGS “s” in biobank “b” for a specific trait. $\beta_{s,b}$ is modelled as a combination of fixed effects (moderators) with realizations \mathbf{w}_s and parameters $\boldsymbol{\alpha}$ (bold characters indicate vectors) and two error terms: the sampling error $\epsilon_{b,s}$ and a
520 biobank-specific random intercept ζ_b (shared by all observed coefficients in that biobank). $\tau^2_{\text{biobank}} = \text{var}(\zeta)$ is the random effect, where $\text{var}(\zeta)$ denotes the variance of the biobank-specific random intercepts ζ .

For every trait, we meta-analyzed up to 13 PGS in the same model. PGS-choice is modelled with the fixed effects, i.e., \mathbf{w}_s only contains a single non-zero entry of 1 indicating which PGS
525 “s” produced $\beta_{s,b}$. With this parameterization, parameters in $\boldsymbol{\alpha}$ directly correspond to the meta-analyzed effect sizes for the different PGS after inverse variance weighting, and the formula above can equivalently be written as:

$$\beta_{s,b} = \beta_{s^*} + \zeta_b + \epsilon_{s,b}$$

Where β_{s^*} is the average effect size for score “s” across all biobanks “*”. To test whether two
530 meta-analyzed effect sizes are significantly different, we compare parameters α_a and α_b with $H_0: \alpha_a - \alpha_b = 0$ using the z-test. We also report results for the t-test (produced by the anova function applied to metafor rma.mv objects) in Supplementary Table 5-6.

We retrieved 95% likelihood-based confidence intervals for τ^2_{biobank} using the confint function (all values are reported in Supplementary Table 4). We further report meta-analyzed
535 AUROC, r^2_{obs} , and r^2_{liab} values produced by weighting studies by their effective sample size⁴⁹ in Supplementary Table 5-6.

Method ranking

To rank methods across traits, we considered just the traits for which CV-tuning and ensemble PGS were available (i.e., all except height and AD), and ranked scores based on
540 their meta-analyzed effect sizes β_{s^*} (see definition above). To avoid counting scores produced by the same summary statistics twice for eGFR/CKD and urate/gout (e.g., for the ranks shown in Figure 3), we applied the following rule: If the continuous phenotype was available in the same number of biobanks as its binary counterpart, we used the continuous phenotype (higher power), otherwise we used the binary phenotype (larger target diversity). This led to
545 consideration of eGFR for SAS, CKD in EUR, urate for SAS, and gout in EUR. We applied the same reasoning when calculating mean and median values of method performances across all traits.

3-level meta-analytic random effects models

For the 3-level meta-analysis, the observed effect-sizes are modelled as follows:

550
$$\beta_{b,m} = \mu_{\beta} + \zeta_{(2)b,m} + \zeta_{(3)b} + \epsilon_{b,m}$$

Where $\beta_{b,m}$ is the observed β -coefficient for method “m” in biobank “b”, μ_{β} is the mean of the distribution of true effect sizes across biobanks and methods, $\zeta_{(2)b,m}$ is the within-biobank random intercept due to the choice of method (level 2) and $\zeta_{(3)b}$ is the random intercept due to target biobank (level 3, shared by all observations in biobank). The estimated parameter

555 $\tau^2_{\text{biobank}} = \tau^2_{(3)} = \text{var}(\zeta_{(3)})$ quantifies the heterogeneity of effect sizes due to target biobank, and $\tau^2_{\text{method}} = \tau^2_{(2)} = \text{var}(\zeta_{(2)})$ quantifies the heterogeneity of effect sizes due to choice of method within biobank⁵⁰. In contrast to the model introduced in the previous section, method effects are considered nested within biobanks (independent between biobanks).

All models were fit using restricted maximum-likelihood with the metafor package in R

560 (rma.mv function), using the V-argument to account for the dependence of effect-sizes measured within the same biobanks (see below). We retrieved 95% likelihood-based confidence intervals for τ^2_{biobank} and τ^2_{method} using the confint function. To calculate $I^2_{\text{biobank}} = I^2_{(3)}$ and $I^2_{\text{method}} = I^2_{(2)}$, we used the implementation provided in dmetar⁵⁰

(var.comp/mlm.variance.distribution function,

565 <https://github.com/MathiasHarrer/dmetar/blob/master/R/mlm.variance.distribution.R>, commit 21bde652cbae5677b56b0ff848eb96c9bea877d8) based on the three-level extension of the I^2 metric⁵¹. I^2_{biobank} captures the fraction of the overall variance in effect sizes (including sampling error) attributable to biobank (level 3) and I^2_{method} captures the fraction of the overall variance in effect sizes attributable to methods within biobank (level 2).

570 Accounting for dependent effect sizes in meta-analytic models

Within each biobank, ancestry, and trait, we calculated pairwise correlations between polygenic scores based on up to 50,000 randomly sampled individuals. We use the resulting score-score correlation matrix R_b (where “b” indicates the biobank) to estimate V_b , the variance-covariance matrix capturing the dependency of errors of effect size estimates for

575 biobank “b”:

$$V_b = S_b R_b S_b$$

Where S_b is a diagonal matrix containing the standard errors of the estimated effect sizes corresponding to the rows/columns of R_b . The effect sizes measured in different biobanks are considered independent, therefore, the full matrix V supplied to the rma.mv function is a

580 block diagonal matrix containing all V_b for the different biobanks b from 1 to n on the diagonal:

$$V = \begin{pmatrix} V_1 & 0 & 0 \\ 0 & \ddots & 0 \\ 0 & 0 & V_n \end{pmatrix}$$

Where 0 denotes a matrix of zeros with the same shape the different V_b .

Calculating PGS variance in the HLA-region

585 For the phenotypes T1D and RA, we scored individuals in the 1000 Genomes EUR subset using either all PGS variants, or only variants contained in the HLA region (defined as the interval 28,000,000-34,000,000 on chromosome 6). The fraction of variance was then computed by dividing the variance of HLA-only PGS by that of the full PGS.

Data availability and interactive data visualizations

590 The prspipe workflow used to generate polygenic score weights, perform polygenic scoring and ancestry matching is available on GitHub (<https://github.com/intervene-EU-H2020/prspipe>).

Genotypes and linked healthcare records held in biobanks are controlled access data and are not publicly available. An application must be made to each biobank to gain access to the data. The 1000 genomes processed genotype data (HapMap3-1KG) are available on figshare (10.6084/m9.figshare.20802700). Non-sensitive experimental data exported from the biobanks are permissively licensed and deposited in an open data repository (<https://zenodo.org/doi/10.5281/zenodo.10012995>). Processed summary statistics are permissively licensed and hosted on GitHub and accessible through in an R data package (<https://github.com/intervene-EU-H2020/pgsCompaR>). A website containing an interactive results browser is permissively licensed and available on GitHub (<https://github.com/intervene-EU-H2020/pgs-method-compare>), hosted at <https://methodscomparison.intervenegeneticscores.org/>.

605 Polygenic score weights for scores that were at least nominally significantly associated with the phenotype ($p < 0.05$) in all EUR target data samples are made publicly available through the GWAS catalog (<https://www.ebi.ac.uk/gwas/>) with publication ID PGP000517. All evaluated scores except the one produced by LDpred2-auto for Arthritis met this threshold. A list of PGS catalog score IDs is provided in Supplementary Table 15.

Acknowledgements

610 This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101016775, the Hasso Plattner Foundation (HPF) and EMBL-EBI Core Funds. M.I. is supported by core funding from the British Heart

Foundation (RG/18/13/33946) and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014; NIHR203312).

615 This research has been conducted using the UK Biobank Resource under Application Number 78537. Ethics approval for the UK Biobank study was obtained from the North West Centre for Research Ethics Committee (11/NW/0382).

The genotyping in Trøndelag Health Study and work presented here was approved by the Regional Committee for Ethics in Medical Research, Central Norway (2014/144, 2018/1622, 620 2018/411492). All participants signed informed consent for participation and the use of data in research.

The activities of the Estonian Biobank are regulated by the Human Genes Research Act, which was adopted in 2000 specifically for the operations of the Estonian Biobank.

Individual level data analysis in the Estonia Biobank was carried out under ethical approval 625 1.1-12/624 from the Estonian Committee on Bioethics and Human Research (Estonian Ministry of Social Affairs), using data according to release application S22, document number 6-7/GI/16259 from the Estonian Biobank.

Patients and control subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior 630 the Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea (Finnish Medicines Agency), the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) statement number for the FinnGen study is Nr HUS/990/2017.

The FinnGen study is approved by Finnish Institute for Health and Welfare (permit numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019 and THL/1524/5.05.00/2020), Digital and population data service agency (permit numbers: 640 VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, KELA 134/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA 16/522/2020), Findata permit numbers THL/2364/14.02/2020, THL/4055/14.06.00/2020,,THL/3433/14.06.00/2020, THL/4432/14.06/2020, 645 THL/5189/14.06/2020, THL/5894/14.06.00/2020, THL/6619/14.06.00/2020, THL/209/14.06.00/2021, THL/688/14.06.00/2021, THL/1284/14.06.00/2021,

THL/1965/14.06.00/2021, THL/5546/14.02.00/2020, THL/2658/14.06.00/2021,
THL/4235/14.06.00/202, Statistics Finland (permit numbers: TK-53-1041-17 and
TK/143/07.03.00/2020 (earlier TK-53-90-20) TK/1735/07.03.00/2021,
650 TK/3112/07.03.00/2021) and Finnish Registry for Kidney Diseases permission/extract from
the meeting minutes on 4th July 2019.

The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data
Freeze 9 include: THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34,
BB_2018_67, BB2018_71, BB2019_7, BB2019_8, BB2019_26, BB2020_1, Finnish Red
655 Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, HUS/248/2020,
Auria Biobank AB17-5154 and amendment #1 (August 17 2020), AB20-5926 and
amendment #1 (April 23 2020) and it's modification (Sep 22 2021), Biobank Borealis of
Northern Finland_2017_1013, Biobank of Eastern Finland 1186/2018 and amendment 22 §
/2020, Finnish Clinical Biobank Tampere MH0004 and amendments (21.02.2020 &
660 06.10.2020), Central Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001 and
amendment 25th Aug 2020.

Genes & Health is/has recently been core-funded by Wellcome (WT102627, WT210561), the
Medical Research Council (UK) (M009017, MR/X009777/1, MR/X009920/1), Higher
Education Funding Council for England Catalyst, Barts Charity (845/1796), Health Data
665 Research UK (for London substantive site), and research delivery support from the NHS
National Institute for Health Research Clinical Research Network (North Thames). Genes &
Health is/has recently been funded by Alnylam Pharmaceuticals, Genomics PLC; and a Life
Sciences Industry Consortium of Astra Zeneca PLC, Bristol-Myers Squibb Company,
GlaxoSmithKline Research and Development Limited, Maze Therapeutics Inc, Merck Sharp
670 & Dohme LLC, Novo Nordisk A/S, Pfizer Inc, Takeda Development Centre Americas Inc.
Ethics approval for Genes & Health was obtained from the London South East Research
Ethics Committee (IRAS 146051). We thank Social Action for Health, Centre of The Cell,
members of our Community Advisory Group, and staff who have recruited and collected data
from volunteers. We thank the NIHR National Biosample Centre (UK Biocentre), the Social
675 Genetic & Developmental Psychiatry Centre (King's College London), Wellcome Sanger
Institute, and Broad Institute for sample processing, genotyping, sequencing and variant
annotation. We thank: Barts Health NHS Trust, NHS Clinical Commissioning Groups (City
and Hackney, Waltham Forest, Tower Hamlets, Newham, Redbridge, Havering, Barking and
Dagenham), East London NHS Foundation Trust, Bradford Teaching Hospitals NHS
680 Foundation Trust, Public Health England (especially David Wyllie), Discovery Data

Service/Endeavour Health Charitable Trust (especially David Stables), Voror Health Technologies Ltd (especially Sophie Don), NHS England (for what was NHS Digital) - for GDPR-compliant data sharing backed by individual written informed consent. Most of all we thank all of the volunteers participating in Genes & Health.

685 We would like to thank Vishnu Raj, Giulia Brunelli, Zhiyu Wang, Ying Wang, Kimmo Mattila, Anne Carson, Julius Anckar, Uwe Ohler and all members of INTERVENE who gave feedback, answered questions, or otherwise facilitated the development of this project.

[Author Disclosures and Declaration of Interests](#)

M.I. is a trustee of the Public Health Genomics (PHG) Foundation, a member of the Scientific Advisory Board of Open Targets, and has a research collaboration with
690 AstraZeneca PLC which is unrelated to this study. M.I. is supported by core funding from the British Heart Foundation (RG/18/13/33946) and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014; NIHR203312). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

695 O.P. provides consultancy services for UCB pharma company.

Supplementary Results

CV versus automatic tuning

700 Out of 14 traits, the score generated by automatic tuning was selected via CV six times for PRScs, four times for lassosum and one time for LDpred2 (of note, PRScs explores only a small grid of hyperparameters). Consequentially, we could only test for significant differences ($H_0: \beta_{CV^*} - \beta_{auto^*} = 0$) in a subset of traits (and these cases were not considered when calculating the medians reported in the main text. We use β_{CV^*} and β_{auto^*} to denote the meta-analyzed effect sizes for CV-tuned or automatically tuned scores of the same method, 705 respectively. For EUR target data, hyperparameter tuning often significantly increased PGS effect sizes (for 10/13 traits for LDpred2, 9/10 for lassosum, 10/14 for MegaPRS and 2/8 for PRScs) and rarely significantly decreased effect sizes, specifically for RA (PRScs and MegaPRS, driven by FinnGen), and CKD (PRScs) (Supplementary Figure 12, FWER ≤ 0.05 , two-sided z-test). For SAS target data, we observed fewer significant performance 710 increases through CV-hyperparameter tuning: 6/13 for LDpred2, 2/9 for lassosum, 2/13 for pT+clump and 1/13 for MegaPRS. Effect-sizes never significantly increased for PRScs, and it was the only method that saw a significant reduction in effect size for this ancestry group (BMI) (Supplementary Figure 13, FWER ≤ 0.05 , two-sided z-test).

715

study	GWAS trait	N _{cas}	N _{con}	N _{variants}	target traits
GCST005838 ⁵²	Stroke	67,162	454,450	1,121,867	Stroke
GCST90012877 ⁵³	AD or family history of AD	53,042	355,900	1,136,233	AD
GCST90013534 ⁵⁴	Rheumatoid arthritis	22,628	288,664	778,275	Rheumatoid arthritis
GCST004773 ³⁶	T2D	26,676	132,532	1,071,786	T2D
GCST004988 ⁵⁵	Breast cancer	76,192	63,082	1,137,481	Breast cancer
GCST006085 ⁵⁶	Prostate cancer	79,148	61,106	1,139,693	Prostate cancer
GCST90013445 ³³	T1D	22,153	37,374	63,204	T1D
GCST004131 ⁵⁷	IBD	25,042	34,915	1,103,333	IBD
GCST008059 ⁵⁸	eGFR	567,460	-	1,141,659	CKD, eGFR
GCST90018959 ⁵⁹	Height	525,444	-	1,119,889	Height
GCST008972 ³⁴	Urate levels	457,690	-	1,005,478	Gout, Urate
GCST002783 ⁶⁰	BMI	236,781	-	1,039,042	BMI
GCST007140 ⁶¹	HDL	94,674	-	1,138,452	HDL
GCST007954 ³⁵	HbA1c	88,355	-	1,009,664	HbA1c

Table 1: GWAS summary statistics used to derive PGS weights

720 Entries are ordered by the total sample size and type of trait (binary, continuous). From left to right: GWAS catalog study identifiers (study), the respective reported GWAS traits, number of cases (N_{cas}) and controls (N_{con}), the number of variants after intersection with HapMap3-1KG and quality control (N_{variants}), and the evaluated target traits. Scores constructed from urate and eGFR summary statistics were also evaluated for gout and CKD, respectively. The GWAS for T1D considered only a small panel of variants of which 84% remained after intersection and QC.

725

	EUR total	SAS total	EUR ebb	EUR finngen	EUR hunt	EUR ukbb(test)	EUR ukbb(train)	SAS gnh	SAS ukbb
AD	15,940	-	555	13,823	1,562	-	-	-	-
Arthritis	13,060	60	2,384	9,332	1,139	205	820	60	-
Breast cancer	23,610	393	2,685	16,076	1,729	3,120	12,483	197	196
CKD	19,714	1,609	4,224	9,314	2,802	3,374	13,496	1,131	478
Gout	22,399	488	10,646	8,759	1,318	1,676	6,704	282	206
IBD	13,016	634	2,097	7,815	1,769	1,335	5,340	466	168
Prostate cancer	20,492	205	2,227	13,606	2,242	2,417	9,671	95	110
Stroke	37,920	635	4,515	26,166	5,204	2,035	8,142	424	211
T1D	5,384	443	501	4,286	396	201	804	443	-
T2D	81,487	8,696	12,344	59,345	3,861	5,937	23,748	6,630	2,066
BMI	346,290	42,243	189,651	-	66,663	89,976	359,913	33,146	9,097
HDL	139,248	37,693	10,642	-	49,824	78,782	315,135	29,628	8,065
HbA1c	120,242	21,696	-	-	34,192	86,050	344,209	12,948	8,748
Height	524,056	43,197	190,013	267,343	66,700	-	-	34,089	9,108
Urate	85,973	13,572	-	-	-	85,973	343,904	4,730	8,842
eGFR	152,793	38,916	-	-	66,759	86,034	344,140	3,061	8,855

Table 2: Target sample sizes across traits.

For each trait and replicated ancestry group (EUR, SAS) the number of cases (binary disease traits) or sample size are shown, either combined (“total”, excluding UKBB training data) or separated by biobank. For the UKBB-EUR, data were split into train (80%, used to tune hyperparameters and ensemble PGS) and test sets (20%, used for evaluation and meta-analyses). UKBB EUR data were excluded for Alzheimer’s disease and height due to sample overlap and could therefore not be used for tuning (leaving 14 traits for a full evaluation). Dashes “-” indicate the phenotype was unavailable.

735

method	tuning type	trait	N (EUR)	N (SAS)	median (EUR)	median (SAS)	mean (EUR)	sd (EUR)	mean (SAS)	sd (SAS)
ldpred2	CV	binary	9	8	0.965	0.963	0.943	0.045	0.972	0.127
megaprs	CV	binary	9	8	0.957	0.934	0.947	0.041	0.958	0.124
lassosum	CV	binary	9	8	0.921	0.914	0.913	0.061	0.920	0.111
prscs	CV	binary	9	8	0.903	0.900	0.896	0.100	0.909	0.259
pt.clump	CV	binary	9	8	0.735	0.734	0.721	0.077	0.748	0.186
megaprs	auto	binary	9	8	0.948	0.950	0.933	0.050	0.964	0.104
ldpred2	auto	binary	9	8	0.927	0.955	0.838	0.265	0.904	0.314
prscs	auto	binary	9	8	0.925	0.876	0.915	0.052	0.877	0.264
sbayesr	auto	binary	9	8	0.907	0.895	0.873	0.083	0.841	0.181
dbslmm	auto	binary	9	8	0.904	0.865	0.890	0.092	0.815	0.199
lassosum	auto	binary	9	8	0.891	0.870	0.861	0.103	0.753	0.262
pt.clump	auto	binary	9	8	0.629	0.627	0.607	0.098	0.527	0.302
ldpred2	CV	continuous	5	5	0.950	0.936	0.948	0.016	0.925	0.049
megaprs	CV	continuous	5	5	0.927	0.931	0.940	0.024	0.946	0.034
prscs	CV	continuous	5	5	0.923	0.926	0.909	0.031	0.875	0.090
lassosum	CV	continuous	5	5	0.906	0.920	0.914	0.026	0.916	0.021
pt.clump	CV	continuous	5	5	0.735	0.729	0.743	0.037	0.718	0.048
prscs	auto	continuous	5	5	0.923	0.928	0.907	0.028	0.903	0.076
dbslmm	auto	continuous	5	5	0.901	0.904	0.891	0.039	0.897	0.066
sbayesr	auto	continuous	5	5	0.887	0.862	0.868	0.075	0.806	0.184
megaprs	auto	continuous	5	5	0.883	0.907	0.885	0.067	0.922	0.055
lassosum	auto	continuous	5	5	0.873	0.890	0.877	0.021	0.901	0.054
ldpred2	auto	continuous	5	5	0.851	0.778	0.823	0.121	0.781	0.114
pt.clump	auto	continuous	5	5	0.643	0.614	0.606	0.088	0.635	0.112

Table 3: PGS meta-analyzed β coefficients relative to the ensemble PGS ($\beta_{s^*}/\beta_{\text{EnsPGS}^*}$)

For the 14 traits for which we tuned hyperparameters with CV, relative PGS effect sizes relative the ensemble PGS are shown ($\beta_{s^*}/\beta_{\text{EnsPGS}^*}$) stratified by PGS method, tuning type (CV/auto), ancestry (EUR, SAS) and type of trait (binary/continuous). The number of traits (N), medians, means and standard deviations (sd) are shown. Methods are ordered by the median EUR relative effect size within traits and tuning types.

trait	N _{biobank}	N _{method}	$\mu_{\beta} \pm sd$	$\tau_{biobank}$ (95% CI)	τ_{method} (95% CI)	I ² _{biobank} (%)	I ² _{method} (%)
T1D	3	5*	0.815 ±0.05	0.072 (0-0.383)	0.069(0.046-0.112)	48.8	45
Prostate cancer	4	6	0.664 ±0.029	0.054 (0.024-0.167)	0.02(0.015-0.029)	82.2	11
Breast cancer	4	6	0.537 ±0.017	0.029 (0-0.1)	0.014(0.012-0.02)	67.1	16.5
Gout	4	5*	0.522 ±0.05	0.098 (0.049-0.294)	0.018(0.014-0.028)	94.7	3.3
IBD	4	6	0.513 ±0.089	0.177 (0.092-0.525)	0.019(0.015-0.028)	97.8	1.1
RA	4	5*	0.458 ±0.087	0.165 (0.067-0.522)	0.095(0.068-0.144)	74.4	24.7
T2D	4	6	0.428 ±0.017	0.031 (0.013-0.099)	0.015(0.012-0.02)	77.8	17.2
CKD	4	6	0.213 ±0.031	0.059 (0.028-0.18)	0.006(0.006-0.01)	93.4	0.9
Stroke	4	6	0.133 ±0.016	0.029 (0.01-0.099)	0.01(0.01-0.016)	78.5	10.4
HDL	3	6	0.303 ±0.02	0.035 (0.016-0.148)	0.005(0.005-0.009)	96.2	2.3
BMI	3	5*	0.282 ±0.006	0.01 (0.01-0.046)	0.004(0.004-0.004)	80.2	13.8
eGFR	2	6	0.267 ±0.046	0.065 (0.025-0.733)	0.009(0.009-0.015)	97.9	1.8
HbA1c	2	6	0.172 ±0.013	0.018 (0.011-0.211)	0.005(0.005-0.009)	88.3	7.5

Table 4: 3-level meta-analytical random effects model results (EUR)

745 Table corresponding to Figure 4. From left to right, the target trait, the number of biobanks
with the trait (N_{biobank}), the number of methods/scores considered (N_{method}), the meta-analyzed
average PGS effect size across methods/scores and biobanks (μ_{β}) with standard deviation
(sd), the standard deviation of the random intercepts specific to biobanks ($\tau_{biobank}$) including
95% likelihood-based confidence intervals (95% CI), the standard deviation of the random
750 intercepts specific to methods within biobanks (τ_{method}) including 95% CI, the fraction of total
effect size variance due to heterogeneity between biobanks (I²_{biobank}) in %, and the fraction of
the total effect size variance due to heterogeneity between methods (I²_{method}) in %. Endpoints
are ordered by type (binary/continuous) and μ_{β} . SBayesR was excluded for RA, T1D, gout,
and BMI (*). Full results for EUR and SAS are given in Supplementary Table 9-12

755





Figure 1: prspipe workflow and application.

Prspipe is a snakemake workflow that automates within-biobank method comparisons introduced by Pain et al.¹⁷ The public stage uses only public data (e.g., summary statistics, ancestry reference, PGS software) to derive PGS weights using seven methods from GWAS
760 summary statistics. The private stage requires access to target genotype and phenotype data and includes data harmonization, polygenic scoring, and PGS tuning using cross-validation (CV). We used prspipe to generate PGS weights and tune hyperparameters in the UKBB EUR data (full run). PGS weights were shared with other biobanks for evaluation/replication
765 (skipping the public stage). Other biobanks were not used for hyperparameter tuning. Downstream analyses were conducted to determine PGS performance using a meta-analytical framework (not part of the workflow), and results were published as an online resource at <https://methodscomparison.intervenegeneticscores.org>.



770

Figure 2: Meta-analysis workflow for methods comparison, example: type 2 diabetes.

775

780

785

a) PGS effect sizes $\beta_{s,b}$ (i.e., the change in log odds-ratio per PGS standard deviation measured for scores “s” across biobanks “b”, see Methods) with 95% confidence intervals for all PGS methods (x-axis) stratified by biobank, replicated ancestries (EUR, SAS) and tuning types (auto, CV) serve as the inputs for the meta-analysis (shown for example trait type 2 diabetes). We evaluated scores for seven methods shown on the right, as well as the UKBB-EUR-tuned ensemble PGS (EnsPGS). The largest effect size for each ancestry and biobank is marked with a triangle (given by the ensemble in all cases). $\beta_{s,b}$ for all target data and traits are displayed in Supplementary Figure 1 and browsable online. b) PGS effect-sizes are meta-analyzed within ancestries across biobanks (yielding a single β_{s*} for each score “s”). Effect-size differences relative to the largest meta-analyzed effect size (β_{top*} , given by the ensemble) and 95% confidence intervals are shown. All pairwise differences are available in Supplementary Table 5-6, and browsable online. c) Meta-analyzed effect sizes β_{s*} are compared, and significance testing is performed. Heatmaps show both the effect-size relative to the largest ($\beta_{s*} / \beta_{top*}$, left) as well as corresponding two-sided z-test significance levels at which $H_0: \beta_{s*} - \beta_{top*} = 0$ can be rejected (right). Significant differences at a FWER ≤ 0.05 are marked with an asterisk (*), accounting for all 351 tests performed across traits and ancestries. The score against which comparisons are performed with effect size β_{top*} is marked with a “1” and black border. Arrows indicate two example comparisons: against

790 PRScs-CV (significant difference in SAS and EUR) and LDpred2-auto (significant only in EUR). Data for all PGS and traits are provided in Supplementary Figure 6





Figure 3: Relative meta-analyzed PGS effect sizes across 14 traits

795 a) For the 14 traits for which we tuned hyperparameters using CV (x-axis), we show
 heatmaps of meta-analyzed β -coefficients relative to the highest within traits ($\beta_{s^*} / \beta_{top^*}$, left) as
 well as significance levels for the two-sided z-test ($H_0: \beta_{s^*} - \beta_{top^*} = 0$, right) stratified by
 ancestry (EUR, SAS). The top score with the largest effect size for each trait (β_{top^*}) is marked
 with a "1" and black box. Differences significant at FWER ≤ 0.05 are marked with asterisks
 800 (*), accounting for all 351 pairwise tests performed across traits, replicated ancestries and
 tuning types (auto, CV) (full data for all traits and scores are displayed in Supplementary
 Figure 6). b) Bar plot counting PGS ranks across traits (1 is the highest), stratified by
 ancestry, method, and tuning-type (auto, CV). Methods are ordered by the average rank-sum
 across tuning types (highest to lowest). c) For each method (y-axis), dot plots showing the
 805 relative meta-analyzed effect-size of the score derived using methods' automatic settings

against the CV-tuned scores ($\beta_{\text{auto}^*}/\beta_{\text{CV}^*}$). Colors denote sign and significance of the two-sided z-test ($H_0: \beta_{\text{CV}^*} - \beta_{\text{auto}^*} = 0$) at FWER ≤ 0.05 after accounting for 114 tests across traits and ancestries (Supplementary Figure 12-13). Methods are ordered by the median difference.



810

Figure 4: 3-level meta-analysis of PGS effect sizes in EUR target data

For all 13 traits replicated in at least 2 biobanks in EUR ancestry target data and CV-tuned in UKBB, from left to right: 1) PGS effect sizes (β -coefficients, $\beta_{m,b}$) with 95% confidence intervals for three example traits within biobanks (T1D: high variability between methods, IBD: high variability between biobanks, T2D: intermediate to low variability between methods and biobanks), 2) the meta-analyzed average effect sizes across biobanks and methods (μ_β) with bars denoting the square roots of the variance components (τ), i.e., the standard deviations of the random intercepts for biobanks or methods, 3) τ -values with likelihood-based 95% confidence intervals and 4) I^2 estimates, i.e., the fraction of variance of effect sizes explained by heterogeneity between biobanks or methods within biobanks. τ and I^2 are colored according to the levels of the meta-analytic 3-level random effects model (Methods).

820

1. Lee, A. *et al.* BOADICEA: a comprehensive breast cancer risk prediction model
825 incorporating genetic and nongenetic risk factors. *Genetics in Medicine* **21**, 1708–1718
(2019).
2. Weale, M. E. *et al.* Validation of an Integrated Risk Tool, Including Polygenic Risk
Score, for Atherosclerotic Cardiovascular Disease in Multiple Ethnicities and Ancestries.
The American Journal of Cardiology **148**, 157–164 (2021).
- 830 3. Mars, N. *et al.* Polygenic and clinical risk scores and their impact on age at onset and
prediction of cardiometabolic diseases and common cancers. *Nat Med* **26**, 549–557
(2020).
4. Mars, N. *et al.* Systematic comparison of family history and polygenic risk across 24
common diseases. *The American Journal of Human Genetics* **109**, 2152–2162 (2022).
- 835 5. Khera, A. V. *et al.* Genome-wide polygenic scores for common diseases identify
individuals with risk equivalent to monogenic mutations. *Nature genetics* **50**, 1219–1224
(2018).
6. Lewis, C. M. & Vassos, E. Polygenic risk scores: From research tools to clinical
instruments. *Genome Medicine* **12**, 1–11 (2020).
- 840 7. Adeyemo, A. *et al.* Responsible use of polygenic risk scores in the clinic: potential
benefits, risks and gaps. *Nat Med* **27**, 1876–1884 (2021).
8. Marston, N. A. *et al.* Predicting Benefit From Evolocumab Therapy in Patients With
Atherosclerotic Disease Using a Genetic Risk Score. *Circulation* **141**, 616–623 (2020).
9. Damask, A. *et al.* Patients With High Genome-Wide Polygenic Risk Scores for Coronary
845 Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the
ODYSSEY OUTCOMES Trial. *Circulation* **141**, 624–636 (2020).
10. Mak, T. S. H., Porsch, R. M., Choi, S. W., Zhou, X. & Sham, P. C. Polygenic scores via
penalized regression on summary statistics. *Genetic Epidemiology* **41**, 469–480 (2017).

11. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic prediction via
850 Bayesian regression and continuous shrinkage priors. *Nat Commun* **10**, 1776 (2019).
12. Lloyd-Jones, L. R. *et al.* Improved polygenic prediction by Bayesian multiple regression
on summary statistics. *Nat Commun* **10**, 5086 (2019).
13. Privé, F., Arbel, J. & Vilhjálmsson, B. J. LDpred2: Better, faster, stronger. *Bioinformatics*
36, 5424–5431 (2020).
- 855 14. Yang, S. & Zhou, X. Accurate and Scalable Construction of Polygenic Scores in Large
Biobank Data Sets. *The American Journal of Human Genetics* **106**, 679–693 (2020).
15. Zhang, Q., Privé, F., Vilhjálmsson, B. & Speed, D. Improved genetic prediction of
complex traits from individual-level data or summary statistics. *Nature Communications*
12, 1–9 (2021).
- 860 16. Jermy, B. *et al.* A unified framework for estimating country-specific cumulative
incidence for 18 diseases stratified by polygenic risk. 2023.06.12.23291186 Preprint at
<https://doi.org/10.1101/2023.06.12.23291186> (2023).
17. Pain, O. *et al.* Evaluation of polygenic prediction methodology within a reference-
standardized framework. *PLoS Genetics* **17**, 1–22 (2021).
- 865 18. Köster, J. *et al.* Sustainable data analysis with Snakemake. *F1000Research* **10**, (2021).
19. Sudlow, C. *et al.* UK Biobank: An Open Access Resource for Identifying the Causes of a
Wide Range of Complex Diseases of Middle and Old Age. *PLOS Medicine* **12**, 1–10
(2015).
20. Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated
870 population. *Nature* **613**, 508–518 (2023).
21. Leitsalu, L. *et al.* Cohort Profile: Estonian Biobank of the Estonian Genome Center,
University of Tartu. *Int J Epidemiol* **44**, 1137–1147 (2015).

22. Åsvold, B. O. *et al.* Cohort Profile Update: The HUNT Study, Norway. *International Journal of Epidemiology* **52**, e80–e91 (2023).
- 875 23. Finer, S. *et al.* Cohort Profile: East London Genes & Health (ELGH), a community-based population genomics and health study in British Bangladeshi and British Pakistani people. *International Journal of Epidemiology* **49**, 20–21i (2020).
24. MacArthur, J. *et al.* The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog). *Nucleic Acids Research* (2017) doi:10.1093/nar/gkw1133.
- 880 25. Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**, 68–74 (2015).
26. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4**, s13742-015 (2015).
27. Martin, A. R. *et al.* Clinical use of current polygenic risk scores may exacerbate health
885 disparities. *Nat Genet* **51**, 584–591 (2019).
28. Lambert, S. A. *et al.* The Polygenic Score Catalog as an open database for reproducibility and systematic evaluation. *Nature Genetics* **53**, 420–425 (2021).
29. Privé, F., Albiñana, C., Arbel, J., Pasaniuc, B. & Vilhjálmsón, B. J. Inferring disease architecture and predictive ability with LDpred2-auto. 2022.10.10.511629 Preprint at
890 <https://doi.org/10.1101/2022.10.10.511629> (2023).
30. Norland, K., Schaid, D. J. & Kullo, I. J. A linear weighted combination of polygenic scores for a broad range of traits improves prediction of coronary heart disease. *Eur J Hum Genet* 1–6 (2023) doi:10.1038/s41431-023-01463-0.
31. Krapohl, E. *et al.* Multi-polygenic score approach to trait prediction. *Mol Psychiatry* **23**,
895 1368–1374 (2018).
32. Albiñana, C. *et al.* Multi-PGS enhances polygenic prediction by combining 937 polygenic scores. *Nat Commun* **14**, 4702 (2023).

33. Robertson, C. C. *et al.* Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes. *Nat Genet* **53**, 962–971 (2021).
34. Tin, A. *et al.* Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. *Nat Genet* **51**, 1459–1474 (2019).
35. Wheeler, E. *et al.* Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis. *PLOS Medicine* **14**, e1002383 (2017).
36. Scott, R. A. *et al.* An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans. *Diabetes* **66**, 2888–2902 (2017).
37. Skene, N. G. *et al.* Genetic identification of brain cell types underlying schizophrenia. *Nat Genet* **50**, 825–833 (2018).
38. Altshuler, D. M. *et al.* Integrating common and rare genetic variation in diverse human populations. *Nature* **467**, 52–58 (2010).
39. Gentleman, R. C. *et al.* Bioconductor: open software development for computational biology and bioinformatics. *Genome Biology* **5**, R80 (2004).
40. Hinrichs, A. S. *et al.* The UCSC Genome Browser Database: update 2006. *Nucleic Acids Research* **34**, D590–D598 (2006).
41. World Health Organization. *ICD-10 : international statistical classification of diseases and related health problems : tenth revision*. <https://apps.who.int/iris/handle/10665/42980> (2004).
42. Levey, A. S. *et al.* Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. *Clinical Chemistry* **53**, 766–772 (2007).

43. Price, A. L. *et al.* Long-Range LD Can Confound Genome Scans in Admixed Populations. *The American Journal of Human Genetics* **83**, 132–135 (2008).
44. Charrad, M., Ghazzali, N., Boiteau, V. & Niknafs, A. NbClust: An R Package for
925 Determining the Relevant Number of Clusters in a Data Set. *Journal of Statistical Software* **61**, 1–36 (2014).
45. Kuhn, M. Building Predictive Models in R Using the caret Package. *Journal of Statistical Software* **28**, 1–26 (2008).
46. Friedman, J. H., Hastie, T. & Tibshirani, R. Regularization Paths for Generalized Linear
930 Models via Coordinate Descent. *Journal of Statistical Software* **33**, 1–22 (2010).
47. Lee, S. H., Goddard, M. E., Wray, N. R. & Visscher, P. M. A better coefficient of determination for genetic profile analysis. *Genetic epidemiology* **36**, 214–224 (2012).
48. DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric
935 Approach. *Biometrics* **44**, 837–845 (1988).
49. Wang, Y. *et al.* Global Biobank analyses provide lessons for developing polygenic risk scores across diverse cohorts. *Cell Genomics* **3**, 100241 (2023).
50. Ebert, M. H., Pim Cuijpers, Toshi Furukawa, David. *Doing Meta-Analysis with R: A Hands-On Guide*. (Chapman and Hall/CRC, 2021). doi:10.1201/9781003107347.
- 940 51. Cheung, M. W.-L. Modeling dependent effect sizes with three-level meta-analyses: a structural equation modeling approach. *Psychol Methods* **19**, 211–229 (2014).
52. Malik, R. *et al.* Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet* **50**, 524–537 (2018).

- 945 53. Schwartzenuber, J. *et al.* Genome-wide meta-analysis, fine-mapping and integrative
prioritization implicate new Alzheimer’s disease risk genes. *Nat Genet* **53**, 392–402
(2021).
54. Ha, E., Bae, S.-C. & Kim, K. Large-scale meta-analysis across East Asian and European
populations updated genetic architecture and variant-driven biology of rheumatoid
950 arthritis, identifying 11 novel susceptibility loci. *Annals of the Rheumatic Diseases* **80**,
558–565 (2021).
55. Michailidou, K. *et al.* Association analysis identifies 65 new breast cancer risk loci.
Nature **551**, 92–94 (2017).
56. Schumacher, F. R. *et al.* Association analyses of more than 140,000 men identify 63 new
955 prostate cancer susceptibility loci. *Nat Genet* **50**, 928–936 (2018).
57. de Lange, K. M. *et al.* Genome-wide association study implicates immune activation of
multiple integrin genes in inflammatory bowel disease. *Nat Genet* **49**, 256–261 (2017).
58. Wuttke, M. *et al.* A catalog of genetic loci associated with kidney function from analyses
of a million individuals. *Nat Genet* **51**, 957–972 (2019).
- 960 59. Sakaue, S. *et al.* A cross-population atlas of genetic associations for 220 human
phenotypes. *Nat Genet* **53**, 1415–1424 (2021).
60. Locke, A. E. *et al.* Genetic studies of body mass index yield new insights for obesity
biology. *Nature* **518**, 197–206 (2015).
61. Hoffmann, T. J. *et al.* A large electronic-health-record-based genome-wide study of
965 serum lipids. *Nat Genet* **50**, 401–413 (2018).

Supplementary Tables

970 Detailed column descriptions are provided in the supplementary table file worksheets.

Supplementary Table 1: PGS effect sizes for binary traits within biobanks and ancestries (EUR, SAS)

Supplementary Table 2: PGS effect sizes for continuous traits within biobanks and ancestries (EUR, SAS)

975 **Supplementary Table 3: Pairwise comparisons of all scores within biobanks and ancestries (EUR, SAS)**

Supplementary Table 4: Meta-analyzed effect size estimates for all methods and tuning types (CV, auto) across traits and ancestries (EUR, SAS)

980 **Supplementary Table 5: Pairwise comparisons between meta-analyzed effect size estimates for binary traits for all methods and tuning types (CV, auto) across traits and ancestries (EUR, SAS)**

Supplementary Table 6: Pairwise comparisons between meta-analyzed effect size estimates for continuous traits for all methods and tuning types (CV, auto) across traits and ancestries (EUR, SAS)

985 **Supplementary Table 7: Relative r-squared of methods compared to the ensemble PGS, stratified by tuning type (CV, auto), trait (binary, continuous) and ancestry (EUR, SAS)**

Supplementary Table 8: Average and median relative effect sizes of scores tuned with cross-validation against those tuned using automatic settings across methods and ancestries (EUR/SAS)

990 **Supplementary Table 9: 3-level meta-analytical random effects model results (EUR)**

Supplementary Table 10: 3-level meta-analytical random effects model results (EUR) without excluding SBayesR-auto for arthritis, BMI, gout and T1D

Supplementary Table 11: 3-level meta-analytical random effects model results (SAS)

995 **Supplementary Table 12: 3-level meta-analytical random effects model results (SAS) without excluding SBayesR-auto for BMI, gout and urate**

Supplementary Table 13: Binary Endpoint definitions based on ICD-10/9 codes

Supplementary Table 14: PGS method software versions

Supplementary Table 15: PGS catalog score identifiers

Supplementary Figures

1000 Supplementary Figures 1-5 are provided as separate files.

Supplementary Figure 1: PGS β coefficients within biobanks and ancestries (EUR, SAS) for binary and continuous traits

β coefficients, i.e, the change in log odds ratio (binary traits) or trait standard deviations (continuous traits) per standard deviation of the PGS, across biobanks, ancestries, and phenotypes is shown ($\beta_{s,b}$). Colors represent PGS methods, and method tuning types (CV, auto) are indicated by different markers. The score with the largest effect size within each biobank-ancestry group is marked with a triangle. Error bars denote 95% confidence intervals. Disease labels and GWAS catalog identifiers are given to the right. The data in this plot are browsable online and available in Supplementary Table 1-2.

1010

Supplementary Figure 2: PGS odds ratios per PGS standard deviation within biobanks and ancestries (EUR, SAS) (binary traits)

The change in odds ratio per standard deviation of the PGS (OR), across biobanks, ancestries, and phenotypes is shown. Colors represent PGS methods, and method tuning types (CV, auto) are indicated by different markers. The score with the largest effect size within each biobank-ancestry group is marked with a triangle. Error bars denote 95% confidence intervals. Disease labels and GWAS catalog identifiers are given to the right. The data in this plot are browsable online and available in Supplementary Table 1.

1020

Supplementary Figure 3: PGS area under the receiver operator characteristic curve within biobanks and ancestries (EUR, SAS) (binary traits)

The area under the receiver operator characteristic curve (AUROC) of the PGS, across biobanks, ancestries, and phenotypes is shown. Colors represent PGS methods, and method tuning types (CV, auto) are indicated by different markers. The score with the largest effect size within each biobank-ancestry group is marked with a triangle. Error bars denote 95% DeLong confidence intervals (Methods). Disease labels and GWAS catalog identifiers are

1025

given to the right. The data in this plot are browsable online and available in Supplementary Table 1.

1030 **Supplementary Figure 4: PGS variance explained on the liability scale within biobanks and ancestries (EUR, SAS) (binary traits)**


The variance explained by the PGS on the liability scale (r^2_{liab} , Methods), across biobanks, ancestries, and phenotypes is shown. Colors represent PGS methods, and method tuning types (CV, auto) are indicated by different markers. The score with the largest effect size

1035 within each biobank-ancestry group is marked with a triangle. Error bars denote 95% bootstrap-based confidence intervals (Methods). Disease labels and GWAS catalog identifiers are given to the right. The data in this plot are browsable online and available in Supplementary Table 1.

1040 **Supplementary Figure 5: PGS variance explained on the observed scale within biobanks and ancestries (EUR, SAS) (continuous traits)**

The variance explained by the PGS on the observed scale (r^2), across biobanks, ancestries, and phenotypes is shown. Colors represent PGS methods, and method tuning types (CV, auto) are indicated by different markers. The score with the largest effect size within each


1045 biobank-ancestry group is marked with a triangle. Error bars denote 95% confidence intervals. Disease labels and GWAS catalog identifiers are given to the right. The data in this plot are browsable online and available in Supplementary Table 2.



1050 **Supplementary Figure 6: Relative meta-analyzed PGS effect sizes across 16 traits**

For the all traits (x-axis) we show heatmaps of meta-analyzed β -coefficients relative to the highest ($\beta_{s^*}/\beta_{top^*}$, left) as well as the corresponding significance thresholds for the two-sided z-test ($H_0: \beta_{s^*}-\beta_{top^*}=0$, right) stratified by ancestry (EUR, SAS), method, and tuning type (CV, auto). The score with the largest effect size for each trait (β_{top^*}) is marked with a “1” and black box. Differences significant at $FWER \leq 0.05$ are marked with asterisks (*), accounting for all 351 tests. Pairwise comparisons between all PGS are reported in Supplementary Table 5-6.


1055



1060 **Supplementary Figure 7: Relative meta-analyzed PGS effect sizes across 16 traits**
excluding the ensemble PGS

For the all traits (x-axis) we show heatmaps of meta-analyzed β -coefficients relative to the highest (excluding the ensemble PGS, $\beta_{s^*} / \beta_{top^*}$, left) as well as the corresponding significance thresholds for the two-sided z-test ($H_0: \beta_{s^*} - \beta_{top^*} = 0$, right) stratified by ancestry (EUR, SAS),
 1065 method, and tuning type (CV, auto). The score with the largest effect size for each trait (β_{top^*}) is marked with a "1" and black box. Differences significant at FWER ≤ 0.05 are marked with asterisks (*), accounting for all 351 tests. Pairwise comparisons between all PGS are reported in Supplementary Table 5-6.


1070



Supplementary Figure 8: Meta-analyzed performance of methods relative to the ensemble PGS stratified by type of tuning (CV/auto), trait (binary/continuous) and ancestry (EUR, SAS).

1075 Dot plots showing, for each method (y-axis), the meta-analyzed variance explained (r^2 , on the liability scale for binary traits) or the meta-analyzed β -coefficients relative to the ensemble PGS across traits (every dot represents a single trait), stratified by tuning type (auto/CV) and type of trait (binary/continuous). Horizontal black lines “|” denote the median values. This Figure corresponds to the medians and averages reported in Table 3.


1080



Supplementary Figure 9: Relative PGS effect sizes ($\beta_{s,b}/\beta_{top,b}$) across 16 traits within biobanks and ancestries


We show heatmaps of PGS effect sizes (β -coefficients) relative to the highest ($\beta_{s,b}/\beta_{top,b}$) within biobanks (ebb, finngen, hunt, ukbb, gnh) and ancestries (EUR, SAS) across traits (subpanels). The score with the largest effect size for each trait within each ancestry and biobank ($\beta_{top,b}$) is marked with a “1” and black box. Differences significant at FWER ≤ 0.05 are marked with asterisks (*), accounting for all 915 tests ($H_0: \beta_{s,b} - \beta_{top,b} = 0$, two-sided z-test). All pairwise comparisons are reported in Supplementary Table 3.

1090




Supplementary Figure 10: Relative PGS effect sizes ($\beta_{s,b}/\beta_{top,b}$) across 16 traits within biobanks and ancestries excluding the ensemble PGS

For all traits (x-axis) we show heatmaps of PGS effect sizes (β -coefficients) relative to the highest ($\beta_{s,b}/\beta_{top,b}$) within biobanks (ebb, finngen, hunt, ukbb, gnh) and ancestries (EUR, SAS) across traits (subpanels). The score with the largest effect size for each trait within each ancestry and biobank ($\beta_{top,b}$) is marked with a “1” and black box (excluding the ensemble PGS). Differences significant at $FWER \leq 0.05$ are marked with asterisks (*), accounting for all 915 tests ($H_0: \beta_{s,b} - \beta_{top,b} = 0 = 0$, two-sided z-test). All pairwise comparisons are reported in Supplementary Table 3.



Supplementary Figure 11: Meta-analyzed PGS performance relative to the baseline method pT+clump that uses highly significant variants only

1105 Across all traits, we show meta-analyzed β -coefficient-differences compared to the baseline
 pT+clump-auto ($\beta_{S^*} - \beta_{\text{baseline}^*}$) that uses only highly significant ($p < 1e-8$) SNPs (y-axis). Effect
 sizes are stratified by method, tuning type (CV/auto) and ancestry (EUR/SAS). The score
 with the highest effect size within ancestries and traits is marked with a triangle. Error bars
 denote 95% confidence intervals. CV-tuning could not be performed for AD and height due
 1110 to GWAS sample overlap with the UKBB EUR-ancestry data. All pairwise comparisons are
 reported in Supplementary Table 5-6.




Supplementary Figure 12: Comparison of CV- and automatic tuning in EUR target data

1115


Effect-size differences between CV- and automatically tuned PGS for five methods ($\beta_{CV} - \beta_{auto}$) across traits, including 95% confidence intervals. Both values within biobanks (ebb, finngen, hunt, ukbb) and the meta-analyzed estimates (Meta) are shown. If the auto-score was selected via CV, no differences are shown.

1120



Supplementary Figure 13: Comparison of CV- and automatic tuning in SAS target data.


Effect-size differences between CV- and automatically tuned PGS for five methods ($\beta_{CV} - \beta_{auto}$) across traits, including 95% confidence intervals. Both values within biobanks (gnh, ukbb) and the meta-analyzed estimates (Meta) are shown. If the auto-score was selected via CV, no differences are shown.



1130 **Supplementary Figure 14: τ_{biobank} and τ_{method} estimated in SAS ancestry target data**

Estimates for τ_{biobank} and τ_{method} (x-axis, Methods) for traits available in both the UKBB and GNH SAS ancestry matched target data, including 95% likelihood-based confidence intervals. Endpoints are ordered by the average effect size of scores in that ancestry, from largest (top) to lowest (bottom). τ_{biobank} was not well identifiable in SAS ancestry target data

1135 (just two biobanks represented).




Supplementary Figure 15: Scatterplot of μ_β vs τ_{method} in the 3-level meta-analytic random effects model (EUR)

1140

Scatterplot of the average meta-analyzed PGS β coefficients across methods and biobanks (μ_β , x-axis) vs τ_{method} (y-axis) for the 13 traits available in at least two biobanks and EUR target data, colored by the type of trait (continuous/binary). Lines denote 95% confidence intervals. The two autoimmune diseases RA and T1D displayed the largest differences in effect size between methods within biobanks, as quantified by τ_{method} . These scores also had the highest fraction of variance originating in the HLA region, as shown in Supplementary Figure 16.

1145



1150 **Supplementary Figure 16: PGS variance originating in the HLA region for the scores used to estimate τ_{biobank} and τ_{method} in EUR ancestry target data**

PGS variance originating in the HLA region divided by the total PGS variance (x-axis) calculated on the 1000 Genomes EUR reference data across traits (y-axis, Methods). Values were calculated for the 13 traits available in at least two biobanks and EUR target data for which we estimated τ_{biobank} and τ_{method} . T1D and RA showed the highest fraction of PGS variance originating in the HLA region and had the most variable performance depending on the PGS method, as estimated by τ_{method} (Supplementary Figure 15).

Supplementary Data

1160 **forest_plots_eur.pdf**

Forest plots generated with the metafor package related to the 3-level meta-analysis.

